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Objective: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal 
neurodegenerative disease, associated with an almost exclusive involvement of 
upper and lower motor neurons, although autonomic impairment has also been 
described. Often patients affected by ALS complain of disturbed sleep and sudden 
death during sleep has been reported. To date, few overnight polysomnographic 
studies have been performed and a complete evaluation of autonomic nervous 
system (ANS) during sleep has never been performed before in ALS subjects. The 
aim of our study was to assess macro- and microstructure of sleep, detect any 
sleep disorders and evaluate cardiac ANS in a cohort of ALS patients, in order to 
better characterize the disease and identify novel strategies to improve quality of 
life and possibly prolong life expectancy. 
Methods: 23 patients affected by ALS (16M/7 F, age 26-79, mean 61) were 
compared to 15 healthy controls matched for age and sex. Each subject underwent 
a full-night video-polysomnography. Sleep staging was performed according to 
AASM criteria, assessment of sleep stability was made by means of both CAP 
detection and CPC (cardiopulmonary coupling), evaluation of ANS was made 
with assessment of HRV.  
Results: Compared to controls, ALS patients showed a significant reduction of 
sleep efficiency and of total sleep time, longer sleep latency than controls, 
together with an increased number of WASO, increased N1 sleep and decreased 
N2, N3 and REM sleep. Moreover patients showed a significant reduction of CAP 
rate mainly due to a significant reduction in phase A1 and A2. Compared to 
controls, patients showed significant reductions in: total HRV power during non-
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REM (p=0.005), LF in non-REM (p=0.01) and REM (p=0.003) sleep, and wake 
after sleep onset (WASO) (p=0.06) and also in HF during non-REM (p=0.04) and 
REM (p=0.05) sleep and WASO (p=0.03). CPC analysis showed the patients with 
the most advanced pathology, i.e. those with ALS-FRS<30, had the most unstable 
sleep patterns, with high percentage of LFC and low percentage of HFC (<4%). 
Interpretation: Our results confirm that sleep structure and stability of ALS 
patients is altered, and that there is a subclinical alteration of cardiac autonomic 
control in both sleep and wakefulness, with an impairment of both vagal and 
sympathetic systems. Moreover reduction of CAP rate, analogously to the 
reduction of HRV, may reflect an alteration of cortical circuits wich underlie to 
the organization of sleep and autonomic functions, which are strongly 
interconnected, that in these patients seem to be characterized by a marked 
rigidity, with poor reactivity and reduced adaptability to external or internal 
stimuli. These findings suggest the potential importance of assessment of 






Amyotrophic lateral sclerosis (ALS), also known as Lou gehrig disease o 
Charcot’s disease, is a inexorably progressive, devastating and fatal 
neurodegenerative disease, characterized by progressive degeneration of spinal, 
bulbar and cortical motor neurons and consequent painless paralysis of striatal 
skeletal and bulbar muscle with dysphagia, dysarthria and respiratory impairment. 
So far there are not effective therapies and the death occurs usually within 2-3 
years after disease onset, typically for respiratory failure1,2.  
Classically ALS is considered a pure motor neuron disease, and concomitant 
presence of symptoms and signs involving cognitive domain, sensory, cerebellar 
and autonomic systems suggests alternative diagnoses3,4. Today the evidence of 
concomitant involvement of other systems, including autonomic nervous system, 
is documented in ALS5. 
Sleep fragmentation and sleep disorders may be an early manifestation of ALS, 
although underdiagnosed. Several factors may disturb sleep in ALS patients, 
namely sleep disordered breathing, nocturia, sleep fragmentation, restless legs 
syndrome, nocturnal cramps, pain, depression, poor mobility, difficult in changing 
position, increased salivation and problems in swallowing and difficult cough6–8. 
Particular attention has been paid to the chronic nocturnal respiratory 
insufficiency and hypoventilation9 that commonly anticipate the onset of awake 
respiratory failure due to the physiologic vulnerability of respiration during sleep 
and it is well-known that non invasive ventilation (NIV) increase survival in 
patients affected by ALS6,9.  
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There are many well-documented cases of patients diagnosed with ALS who 
presented extramotor symptoms5,10, including autonomic dysfunction11, namely 
cardiovascular manifestations11, altered sweat12–15, impaired salivary16,17 and 
lacrimary secretions18, alteration of urinary19 and gastrointestinal function20–22. 
Cardiovascular disfunction in ALS has been reported23–28, especially in advanced 
stages of the disease and during sleep; moreover altered cardiac autonomic control 
with predominance of sympathetic system and depresses parasympathetic function 
have been documented11,28, and sudden death and cardiovascular dysfunction due 
to dysautonomia are probably more frequent during sleep in these patients11. 
Alterations of ANS as reduced heart rate variability (HRV) and increased 
sympathetic tone have been identified as mortality risk factors in patients with 
cardiac diseases11,29.  
To date few overnight polysomnographic studies have been performed in patients 
affected by ALS8,30, and a complete evaluation of autonomic nervous system 
(ANS) during sleep, with regard to each sleep stage (NREM-N1-N2-N3 and 
REM) and wakefulness, has never been performed before in these subjects. 
The aim of our study was to evaluate nocturnal sleep of patients affected by ALS, 
in order to assess sleep quality, sleep stability, sleep respiratory function and 
autonomic function during both sleep and wakefulness. In particular we assessed 
ANS in wakefulness, NREM (light and deep) sleep and REM sleep, through HRV 
evaluation by means of a single-lead ECG, recorded during Polysomnography 
(PSG). Moreover we evaluated sleep stability, with CAP detection31, and also 
with Cardiopulmonary Coupling (CPC)32,33. 
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Autonomic Nervous System assessment 
Heartbeat is a vital function; the number of beats per minute (BPM) is defined 
heart rate (HR). HR is not constant, but subject to a range oh physiological 
fluctuations, and the inter-beat difference, or R-R interval, is employed to quantify 
the Heart rate variability (HRV). The most important regulator of cardiac 
electrical activity is ANS, with opposite reaction by sympathetic and 
parasympathetic (vagal) system, the first increasing HR, the second decreasing it, 
up to well-regulate cardiac activity, in relation to internal and external stimuli34,35. 
Factors that may modify HR are: respiration, blood oxygen, physical activity, 
mood, thinking, mental stress, drugs and substances, sleep. In a healthy person 
heart rate presents a physiological variability, that reflects a good adaptability of 
cardiovascular system to continuous external and internal changes36,37. 
HRV assessment permits to get information about sympatho-vagal balance, that 
reflects the adaptability of ANS. Higher HRV is typically a sign of good 
adaptation and is typical of a healthy person, while lower HRV is an indicator of 
reduced adaptability and reflects an alteration in autonomic responses38. 
HRV analysis is used as a simple and non-invasive diagnostic tool to study ANS 
through measure of vagal and sympathetic oscillations both in physiological and 
pathological conditions. Decreased HRV has been found in several pathological 
conditions, not only of cardiovascular system, namely coronary artery disease, 
cardiomyopathy, arterial hypertension, myocardial infarction, heart failure, 
smoking, obesity, chronic obstructive pulmonary disease, renal failure, diabetes, 
stroke, Alzheimer’s disease, leukemia, obstructive sleep apnea, epilepsy, 
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headache, among other38; and it has been described that decreased HRV is a 
predictor of mortality, even in ALS patients11. 
HRV evaluation is based on the assessment of rhythmical oscillations  of 
heartbeats, which represent the sympathetic and vagal modulations of 
cardiovascular function. 
For HRV analysis linear and non-linear methods may be used; linear methods 
including time-domain and frequency-domain parameters39. 
The main parameters obtained by time-domain analysis of HRV are statistical and 
geometrical (see table 1 and table 2 for details)36.  
Statistical measures are: averageNN, SDNN, SDANN, RMSSD, SDNN index, 
NN50 and pNN50. 
Geometrical measures are: HRV triangular index and TINN. 
The main parameters obtained by frequency-domain analysis of HRV are: total 
power spectrum, ULF, VLF, LF, HF, LFnu, HFnu, LF/HF36. 
The VLF component is considered to be a marker of humoral and hormonal 
fluctuations; the HF component is considered a marker of vagal modulation, while 
it is still debated whwther the LF component represents a marker of both 
sympathetic and vagal modulation or if it is a marker of sympathetic 
activation39,40. 
In addition nonlinear/entropy/complexity measures are valuable, typically 
employed on longer time scales to help define multiscale features of time series, 




Autonomic function during sleep 
Autonomic Nervous System activity is influenced by sleep and it changes 
continuously during sleep in relation to different sleep stages. Moreover neuronal 
populations involved in sleep-wake control are localized near the areas involved 
in cardiovascular control, and they are reciprocally interconnected and integrated 
also with central autonomic influences and cardiovascular reflexes. These 
connection and integrations cause sleep-related changes in cardiovascular 
function34,35. In particular sympathetic activity progressively decreases from 
wakefulness to deep sleep, and parasympathetic tone is predominant during the 
whole sleep. For these reasons heart rate (HR) and blood pressure (BP) tend to 
decrease during physiological NREM sleep, with the minimum levels in N3; 
baroreflex (BR) is maximally reduced and HR is maintained slow despite reduced 
BP. Moreover in NREM, every 20-30 seconds, we can observe increases of HR 
and BP, associated to changes in EEG activity (alpha rhythm, K-complexes, Slow 
Waves), or suddenly as a response to an arousing stimuli. In REM sleep there is a 
predominance of sympathetic activity, with HR and BP values analogous to those 
in wakefulness. In REM sleep BR presents a not-uniform behavior, with different 
responses to hypertensive and hypotensive stimuli. Moreover during REM sleep 
we can observe transient HR and BP increases in association with bursts of REMs 
and muscle twitches34.  
 
The microstructure of sleep- The Cyclic Alternating Pattern (CAP) 
EEG activity during NREM sleep presents physiologically continuous 
fluctuations, which are known as Cyclic Alternating Pattern (CAP), consist of 
			 8	
arousal-related phasic events, and sets up the microstructural organization of 
sleep, reflecting the continous oscillations of arousal levels. CAP is organized in 
sequences, and each CAP sequence is made of cycles, and each single CAP cycle 
consists of one A phase, characterized by bursts of sleep phasic events (e.g. Delta 
bursts, Vertex sharp transient, K-complex, intermittent alpha…), followed by a B 
phase, which represents the return to EEG background. In relation to the EEG 
feature of phase A, we can distinguish three different types of phase A (A1, A2, 
and A3). All CAP seqeunces begin with a phase A and end with a phase B. Both 
A and B phases are 2-60 seconds in duration. The absence of CAP for more than 
60 seconds is named NCAP (non-CAP). At least two consecutive CAP cycles are 
needed to define a CAP sequence. A CAP sequence is not interrupted by a stage 
shift within NREM sleep, so a CAP sequence may contain different sleep NREM 
stages. The ammount of CAP sequencies tipically increases immediately before 
the transition from NREM to REM sleep, and end just before REM begins. Infact, 
CAP is characterized by global involvement of cortex and thus EEG 
synchronization is a typical feature; in contrast REM sleep in characterized by 
asynchronous EEG, thus phase A are observed in REM sleep only in pathological 
conditions (e.g. concurently with phasic respiratory events), and consist of 
desynchronized patterns. The number of CAP sequences per hour of NREM sleep 
is named CAP rate31. CAP is normally present in all subjects and presents 
modifications in relations to age, and it may be elicited by external factors (e.g. 
sounds, tactile stimulation) and sleep disorders, namely OSA (obstructive sleep 
apnea) and PLMs (periodic limb disorders). It plays a fundamental role in the 
structural organization of sleep, and it involves not only cerebral activities, but it 
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present a reciprocal influence with ANS and motor functions, with activation of 
these systems during phase A and deactivation during phase B. CAP is an EEG 
marker of sleep stability, and it also reflects the capacity of brain to respond to 
internal and external stimuli also during sleep43–45. High CAP rate is an indicator 
of altered or disturbed sleep, and for this reason it is used in clinical practice in 
addition to standard sleep scoring. 
 
Electrocardiogram-based Cardiopulmonary Coupling (CPC) 
Electrocardiogram (ECG)-based cardiopulmonary coupling (CPC) provides a 
graphical and computational method to represent the behavior of dynamical 
interactions between the cardio-autonomics and respiration during sleep. 
Introduced by Thomas, Goldberger and Colleagues32,33. CPC combines spectral 
information derived from inter-beat interval (R-R) time series and an ECG-
derived respiratory signal. The method reveals two distinct modes of 
cardiopulmonary interaction during non-REM sleep: one in the low frequency 
band (0.01-0.1 Hz) and the other in the high frequency band (0.1-0.4 Hz). These 
modes are termed Low Frequency Coupling (LFC) ad High Frequency Coupling 
(HFC). During REM sleep or wakefulness, the coupling mode is in the very low 
frequency band (0-0.01 Hz), and is termed Very Low Frequency Coupling 
(VLFC). LFC reflects unstable (with more arousals) sleep, while HFC reflect 
stable (deeper) sleep32,33,46. The LFC/HFC classification has been found to 
correlate with the CAP/NCAP classification, while showing low agreement with 
standard sleep staging32. 
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because autonomic function is less influenced by confounding factors, such as 











1. Subjects: Inclusion criteria for the whole study were: age > 18 years, diagnosis of 
ALS and informed consent. Exclusion criteria for the whole study were: 
pregnancy, age < 18 years, and failure to sign an informed consent. Exclusion 
criteria for HRV-CPC assessment were: alterations of heart rhythm, coronary 
artery disease, heart failure, diabetes, major depressive disorder, serious diseases 
kidney or liver disease, cancer, cardioactive drugs (e.g. beta-blockers, beta-
agonists calcium-channels-blockers, antiarrhythmic drugs, SSRI and atypical 
antidepressants, atypical antipsychotics, AchE inhibitors, alpha receptors agonists 
and antagonists).  
The study has been approved by local ethical committee.  
Patients: 24 patients (17 M, 7 F) affected by Amyotrophic Lateral Sclerosis 
referred to outpatients ALS service – University of Cagliari were consecutively 
enrolled. One initially enrolled subject did not enter the study for dead. Three 
patients were excluded from analysis for total sleep time (TST) < 4 hours. The 
remaining 20 patients were evaluated for HRV assessment, and among these, 13 
(8 M, 5 F) were selected for the study and 7 were excluded: 2 because of severe 
OSAS and 5 for artifacts in the ECG, that interfered with a correct evaluation of 
HR.  
Controls: 15 volunteer healthy control subjects age and sex matched with patients 
were enrolled. 
2. Clinical evaluation: All subjects underwent a thorough history, both about 
general conditions and sleep, neurological examination and questionnaires 
specific for sleep and its disorders, namely Epworth sleepiness scale (ESS), 
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Pittsburgh Sleep Questionnaire Index (PSQI), Berlin Questionnaire Index (BQI), 
Restless Legs Syndrome Severity Scale (RLSSS), Rem Behavior Disorder Index 
(RBDI) (see Appendix from 2 to 6). 
3. Instrumental evaluation:  
Polysomnography: Each subject underwent a full video-polysomnographic night 
recording, after an adaptation night, (Morpheus – Micromed®) carried out in a 
standard sound-attenuated sleep laboratory, attended by technician expert in sleep 
assessment, after a night. The following data were included in the 
polysomnographic study: EEG (at least 3 channels: one frontal, one central and 
one occipital, referred to the contralateral earlobe); electrooculogram (electrodes 
placed 1 cm above the right outer cantus and 1 cm below the left outer cantus and 
referred to A1), electromyogram (EMG) of the submental muscle, EMG of 
bilateral tibialis anterior muscles (bipolar derivations with the two electrodes 
placed 3 cm apart on the belly of the anterior tibialis muscle of each leg), and one 
single-lead ECG. Sleep respiratory pattern was assessed by means of nasal airflow 
(nasal pressure cannula), thoracic and abdominal respiratory effort (strain gauge) 
and oxygen saturation (pulse-oximetry) during the same night. Sleep stages, 
respiratory activity and legs activity were scored manually by a clinical 
neurophysiologist expert in sleep medicine at Sleep Disorders Center – University 
of Cagliari, following standard criteria47 on 30-seconds epochs by means of the 
sleep analysis software SleepRT. CAP was scored manually by a neurologist 
expert in sleep medicine at Sleep Disorders Center – University of Parma (Italy), 
according to CAP scoring atlas31. 
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HRV analysis: extraction of HRV features was performed by an expert engineer 
at the Wyss Institute for Biologically Inspired Engineering at Harvard University 
– Boston (MA – USA) using the commercial sotware Matlab®. Continuous 
single-lead ECG signals recorded simultaneously with polysomnohgraphy were 
employed. Before the analysis, each trace was visually evaluated in order to 
identify artifacts which might affect a correct analysis of HR signal, and six 
patients were subsequently excluded. The R peaks were detected on the ECG by 
means of a modified Pan-Tompkins algorithm and the R-R time series were 
obtained48. 
The R-R time series were divided into intervals corresponding to continuous sleep 
stages. Intervals corresponding to sleep stages shorter than 5 minutes or including 
artifacts were excluded from the analysis. For each interval the following features 
were computed: time-domain features, namely mean RR interval, SDNN, 
SDANN, SDNN index, rMSSD, pNN50%, and pNN20%; frequency-domain 
features, namely total power, LF, HF, LF/HF index. Features were then averaged 
by sleep stage (N1, N2, N3, REM and W), and in NREM light sleep (N1-N2) and 
in slow wave sleep (SWS or N3) prior to comparison between patients and 
controls. 
Cardiopulmunary coupling (CPC)32,33: CPC analysis was performed on a 
continuous single-lead ECG recorded during polysomnography. Both RR and 
ECG-derived respiration (EDR) were extracted from the ECG, Outliers due to 
false or missed R-wave detections were removed. The resulting NN interval series 
and its associated EDR were then cubic-spline resampled at 2 Hz. The cross-
spectral power and coherence of these two signals were calculated over a 1024-
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sample (8.5 minutes) window using Fast Fourier Transform applied to 3 
overlapping 512-sample subwindows within the 1024-sample coherence window. 
For each 1024-sample window the product of the coherence and cross-spectral 
power was computed, obtaining a spectrographic representation of 
cardiopulmonary coupling dynamics during sleep, as shown in the example in Fig. 
1. The spectrogram shows an alternation between two distinct modes of 
cardiopolmonary interaction during NREM sleep: Low Frequency Coupling, LFC 
[0.01 Hz-0.1 Hz] and High Frequency Coupling, HFC [0.1 Hz-0.4 Hz]. During 
REM sleep or wakefulness, Very Low Frequency Coupling, VLFC [0 Hz-0.01] is 
present.  
By applying thresholds to the CPC amplitude the percentage of sleep spent in 
LFC, HFC and VLFC modes was computed32. 
Statistical analysis: in order to assess Gaussian distribution of each parameter of 
both groups, the D’Agostino & Person – Normality test was performed. Data 
between the two groups were compared with the unpaired Student t-test in case of 
Gaussian distribution and with the Mann-Whitney test in case of non-parametric 










1. Subjects: Among the 24 patients 5 presented bulbar onset, 1 generalized onset, 18 
spinal onset), mean age was 61 years (range 26-79), mean age at onset disease 
was 57 years (range 25-78), with duration of disease of 4 years (range 1-10). 
Severity of disease, calculated with ALS-FRS (Amyotrophic Lateral Sclerosis – 
Functional Rating Scale)49 (see Appendix 1) was 34.4/48 (range 12-45).  
There were no differences between patients and control subjects in demographical 
data (age and sex). Control subjects were negative for any sleep disorders. One 
initially enrolled subject, did not enter the sleep study for dead. 
2. Clinical evaluation : 
- Sleep questionnaires: (23 patients) 
ESS: 3 patients presented an ESS>10 (mean 5,78 ± 4,42; range 0-17). 
PSQI: mean value obtained was 8,52 ± 4,83 (range 1-18). 
BQI: 15 patients presented high risk for OSAS (obstructive sleep apnoea 
syndrome) 
IRLSSS: 3 patients presented RLS with severity index of 15 in two of 
these subjects and 19 in the other 
RBDI: 5 patients presented a score > 5 
3. Instrumental evaluation 
Polysomnography 
- Sleep macro-structure: Respect to control subjects, patients presented a 
significant reduction of TST (p=0.0002) and sleep efficiency (p=0.0005) 
increase of sleep latency (p=0,264), significant increase of N1 (p=0.0001) 
and of WASO (p=0.0039) and a significant reduction of  phase N2 
			 16	
(p<0.0001), of N3-SWS (p=0.0242) and of REM sleep (p<0.0001). (see 
table 3 for details).  
- Sleep micro-structure (CAP): respect to control subjects, patients 
presented a significant reduction of CAP rate (p=0.0006) due to a marked 
reduction of total number of phases A (p<0.0001), with a reduction of 
percentage of A1, A2 and A3 phases (P<0.0001; p=0.0044; p<0.0001 
respectively) and inversion of A1-A3 percentage. (see table 4 for details) 
- Sleep respiratory function: 3 patients were excluded from analysis of 
respiratory function due to TST<4 hours. Among the other patients (n=20), 
10 resulted to be affected by OSAS: 6 presented mild, 2 moderate, and 2 
severe OSAS. 3 patients not affected by OSAS and 1 patient affected by 
mild OSAS presented nocturnal hypoventilation with SpO2<90% for more 
than 30% of TST. Mean ODI > 3% was 8,57 ± 8,86 (range 0-23,3). Mean 
SpO2 were: during wake 93,07 ± 2,40% (range 65-99,4); in TST 92,09 ± 
2,30% (range 63,4-99,4); in NREM sleep 92,38 ± 2,37 % (range 63,4-
99,2); during REM sleep 91,62 ±3,47 (range 74-99,4). 
- Sleep muscular activity: all patients presented spontaneous muscle 
activity as fasciculations in almost all muscles recorded. 3 patients 
presented a PLM-index>15. 
HRV: respect to the control subject, ALS patients showed significant 
reduction in the following HRV features in frequency-domain both in 
sleep and in wakefulness and in parameters influenced by both 
sympathetic and vagal system: total power in NREM (p=0.005), LF in 
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NREM (p=0.01) and in REM sleep (p=0.003), HF in NREM (p=0.04) and 











The present study confirms that in ALS there is a subclinical involvement of 
Autonomic Nervous System, both in sympathetic and parasympathetic 
components. Infact respect to control subjects, patients presented a reduction of 
HRV features in frequency domain, influenced by both sympathetic (LF) and 
vagal (HF) system, and the alteration of HF was both in wakefulness and in sleep 
(both NREM and REM). 
These findings suggest that in ALS there is an important involvement of cardiac 
ANS, that causes a reduction of heart reactivity to internal and external stimuli, 
leading to increase in mortality for sudden cardiac arrest11,50, that it is known 
occur more frequently at night11. So, reduction of HRV in patients with ALS may 
represent a risk factor for sudden death during sleep. Moreover in these patients 
sleep structure appears to be altered, with reduction of total sleep time, reduction 
of sleep efficiency, reduction of N2-N3 and REM sleep, increase of sleep latency 
and of wake after sleep onset, and reduced CAP rate, mainly due to reduction of 
A1-A2 components, despite patients perceive good quality sleep, as it is 
evidenced from questionnaires. Reduction of CAP rate, analogously to the 
reduction of HRV, may reflect an alteration of cortical circuits wich underlie to 
the organization of sleep and autonomic functions, which are strongly 
interconnected34,35,51, that in these patients seems to be characterized by a marked 






Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease, 
and todate there are no effective therapies.  
Our study confirms that in patients affected by ALS there is a subclinical 
involvement of autonomic nervous system and a marked alteration of sleep, 
confirming the evidences that ALS is not a pure motor neuron disease, but it is a 
multisystemic neurological syndrome.  
Early detection and treatment of dysautonomia and of any sleep disorders, both 
sleep breathing disorders and other sleep disorders, may lead to improvement of 
quality of life and possibly to prolong of life expectancy.  
Moreover considering the cases of sudden death during sleep, the fundamental 
role of sleep in homeostasis and recovery, the relashionships between disturbed 
sleep and cognitive deficits52,53 in neurodegenerative diseases and the well-known 
association between cognitive deficits and poor prognosis in ALS54, and the role 
of nocturnal hypoventilation in anticipating the respiratory failure6, it is 
mandatory, during routine exams, assessing autonomic function and sleep, in 
order to early identify and adequately treat any disorders, with the ultimate aim of 
improving the quality of life and possibly prolonge life expectancy. 
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Figure 1: A cardio-respiratory spectrogram derived from the nocturnal ECG of a 
healthy subject, for whom non-REM sleep shows predominance of a stable sleep 
(peaks in blue regime), although certain time epochs present unstable sleep (peaks 
in red regime). REM, rapid eye movement sleep, and wakefulness are 





















Figure 2: Cardio-respiratory spectrograms derived from the nocturnal ECG of 
four of hour patients. Subject 1 and subject 11, who have an advanced stage 
disease, present the most unstable sleep patterns, with high percentage of LFC and 
low percentage of HFC. 
Subject 15 and subject 17, who have the mildest pathology, present the most 
























AverageNN ms Average of all normal RR intervals 
SDNN ms SD of all normal RR intervals 
SDANN ms SD of the average normal RR inetrvals calculated over 
short time periods 
RMSSD ms The square root of the mean squared differences 
between adjacent normal RR intervals 
SDNN Index ms Mean of the SD of the normal RR intervals calculated 
over short periods time for the entire recording period 
NN50  The number of pairs of adjacent normal RR intervals 
that differ by more than 50 ms 
NN20 ms The number of pairs of adjacent normal RR intervals 
that differ by more than 20 ms 
PNN50 % NN50 divided by the total number of normal RR 




 Number of normal RR intervals divided by the height 
of the istogram of all the normal RR intervals measured 
on discrete scale with bins of 1/128 s 
TINN ms 
 
Baseline width of the minimum square difference of 
triangular interpolation of the highest peak of the 









ms2 Area under the entire power spectral curve, 
variance of all RR intervals 
ULF ms2 Ultra low frequency power (≤0.003 Hz) 
VLF ms2 Very low frequency power (0.003-0.04 Hz) 
LF ms2 Low frequency power (0.04-0.15 Hz) 
HF ms2 High frequency power (0.15-0.40 Hz); (0.24-1.04 
Hz) in infants and exercising adults 
LFnu nu Normalized low frequency power (LF/(LF+HF))  
HFnu nu Normalized high frequency power (HF/(LF+HF)) 
LF/HF  Ratio of the low-to high freqeuncy power 
Nu: Normalized Units 
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Table 3: Features of sleep macrostrustructer of ALS patients and controls 
 
Macro structure 
Feature Pt (mean±sd) C  (mean±sd) pValue 
TST 321.0 ± 97.03 423.0 ± 39,64 0.0002 
SL 35.79 ± 35.17 9.67 ± 6.68 0.0264 
SE% 67.06 ± 16.97 87.88 ± 8.54 0.0005 
WASO (min) 120.61 ± 67.28 49.47 ± 39.55 0.0039 
N1 (min) 79.8 ± 39.01 27.93 ± 22.55 0.0001 
N2 (min) 151.67 ± 51.07 228.67 ± 29.37 < 0.0001 
N3 (min) 51.36 ± 29.12 73.87 ± 34.04 0.0242 








Feature Pt (mean ± sd) C  (mean ± sd) pValue 
CAP rate 30.95 ±  15.05 49.32 ± 10.20 0.0006 
A tot (n°) 174.78 ± 106.32 341.47 ± 59.33 < 0.0001 
A1 Index 9.95 ± 10.43 6.93 ± 8.68 0.2322 
A1 % 25.48 ± 17.49 53.13 ± 10.99 < 0.0001 
A2 Index 7.19 ± 5.71 74.0 ± 29.02 < 0.0001 
A2 % 20.11 ± 8.86 31.51 ± 7.80 0.0044 
A3 Index 17.77 ± 9.87 49.4 ± 19.77 < 0.0001 












Table 5: p value of HRV parameters in time-domain of ALS patients and controls 
 
 




NN SDNN SDANN 
SDNN-
I RMSSD pNN50 pNN20 
NREM 
sleep 
0.264 0.008 0.002 0.009 0.025 0.026 0.022 
REM 
sleep 
0.526 0.231 0.622 0.180 0.016 0.057 0.048 
WASO 0.456 0.214 0.121 0.082 0.054 0.136 0.136 
N1-N2 0.238 0.009 0.001 0.013 0.025 0.029 0.021 
N3 0.291 0.029 0.099 0.029 0.129 0.060 0.166 
REM 0.526 0.231 0.622 0.180 0.016 0.057 0.048 
 
 




Sleep stages Total  power VLF LF HF LF/HF CI 
NREM sleep 0.005 0.022 0.013 0.040 0.852 0.555 
REM sleep 0.231 0.481 0.003 0.048 0.622 0.071 
WASO 0.192 0.385 0.062 0.029 0.756 0.192 
N1-N2 0.006 0.047 0.006 0.018 0.950 0.231 
N3 0.029 0.291 0.047 0.113 0.843 0.029 








APPENDIX 1. Scala di disabilità funzionale ALSFRS-R (ALS Functional 
Rating Scale – Revised) 
 
Fonazione 
4 Normale fonazione 
3 Disturbo rilevabile della fonazione 
2 Comprensibile con ripetizione 
1 Fonazione associata a comunicazione 
non verbale 
0 Comunicazione impossibile 
 
Vestirsi e lavarsi 
4 Normale 
3 Indipendente con sforzo o con ridotta 
efficacia 
2 Assistenza intermittente o modalità 
sostitutive 
1 Necessità di assistenza per la cura 
della persona 




3 Lieve aumento della salivazione; può 
avere perdita di saliva notturna 
2 Moderato eccesso di salivazione; può 
avere minima perdita di saliva 
1 Marcato eccesso di salivazione con 
perdita di saliva 
0 Marcata perdita di saliva; richiede uso 
costante del fazzoletto 
 
Girarsi nel letto e aggiustare le 
lenzuola 
4 Normale 
3 Lento ed impacciato ma non necessita 
di aiuto 
2 Può girarsi o aggiustare le lenzuola da 
solo, ma con grande difficoltà 
1 Può iniziare il movimento ma non 
girarsi o mettere a posto le coperte da 
solo 




3 Iniziali problemi, occasionale 
“strozzamento” 
2 Modificazioni della consistenza della 
dieta 
1 Necessita integrazione con sondino 
naso-gastrico 
0 Alimentazione esclusivamente 




3 Iniziali difficoltà della deambulazione 
2 Cammina con assistenza 
1 Solo movimenti funzionali non 
deambulatori 




3 Lento o disordinato: tutte le parole 
sono leggibili 
2 Non tutte le parole sono leggibili 
1 Capace di impugnare la penna ma non 
di scrivere 
0 Incapace di impugnare la penna 
 
Salire le scale 
4 Normale 
3 Lentamente 
2 Lieve instabilità o fatica 
1 Necessita assistenza 
0 Non in grado 
 
Utilizzo delle posate (alimentazione 
per via orale) 
4 Normale 
3 Rallentato ed impacciato, non 
necessita di aiuto 
2 Può tagliare il cibo, sebbene lento ed 
impacciato; in 
alcuni casi necessita di aiuto 
1 Il cibo deve essere tagliato da altri, 
può alimentarsi da solo lentamente 




3 Dispnea quando cammina 
2 Dispnea con una o più delle seguenti 
azioni: mangiare, lavarsi, vestirsi (ADL) 
1 Dispnea a riposo, difficoltà a respirare 
quando si siede o si sdraia 
0 Significativa difficoltà che consiglia 
l’uso del respiratore 
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Utilizzo delle posate (alimentazione 
per PEG) 
4 Normale 
3 Impacciato ma non necessita di aiuto 
2 Necessita di aiuto 
1 Fornisce un minimo di assistenza al 
personale sanitario 




3 Qualche difficoltà notturna con respiro 
più corto, non usa più di 2 compresse 
2 Necessita più di due cuscini per 
dormire 
1 Può dormire seduto 




3 Intermittente uso di BiLevel 
2 Continuo uso di Bilevel durante la 
notte 
1 Continuo uso di Bilevel sia di notte 
che di giorno 





























APPENDIX 2. Epworth Sleepiness Scale (ESS) 
 
Che probabilità ha di appisolarsi o di addormentarsi nelle seguenti situazioni, 
indipendentemente dalla sensazione di stanchezza? 
 
La domanda si riferisce alle usuali abitudini di vita nell'ultimo periodo. 
Qualora non si sia trovato di recente in alcune delle situazioni elencate sotto, provi ad 
immaginare come si sentirebbe. 
 
Usi la seguente scala per scegliere il punteggio più adatto ad ogni situazione: 
O = non mi addormento mai 
1 = ho qualche probabilità di addormentarmi 
2 = ho una discreta probabilità di addormentarmi 




a. Seduto mentre leggo |____| 
b. Guardando la TV |____| 
c. Seduto, inattivo in un luogo pubblico (a teatro, ad una conferenza) |____| 
d. Passeggero in automobile, per un'ora senza sosta |____| 
e. Sdraiato per riposare nel pomeriggio, quando ne ho l'occasione |____| 
f. Seduto mentre parlo con qualcuno. |____| 
g. Seduto tranquillamente dopo pranzo, senza avere bevuto alcoolici |____| 









APPENDIX 3. INDICE DI QUALITA’ DEL SONNO DI PITTSBURGH 
(PSQI) 
 
1. Nel mese passato a quale ora vi siete di solito coricati? 
2. Nel mese passato, quanto tempo (in minuti) avete impiegato mediamente ad 
addormentarvi ogni sera? 
3. Nel mese passato a che ora vi siete alzato abitualmente? 
4. Nel mese passato quante ore di sonno effettivo ha avuto ogni notte? 
5. Nel mese passato quante volte volte ha avuto problemi di sonno per ciascuno dei 
seguenti motivi? 
• Non vi siete potuti addormentare entro 30 minuti: 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Vi siete svegliati nel mezzo della notte o al mattino presto 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete dovuto fare uso del bagno 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Non avete potuto respirare correttamente 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete tossito o russato rumorosamente 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete avvertito troppo freddo 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete avvertito troppo caldo 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete fatto brutti sogni 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Avete avuto dolori 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Per altri motivi (descriveteli) 
Quante volte nell’ultimo mese non avete dormito bene a causa del suddetto motivo 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
6. Nell’ultimo mese come valutate globalmente la qualità del vostro sonno? 
molto buona abbastanza buona abbastanza cattiva molto cattiva 
7. Nell’ultimo mese quante volte avete assunto farmaci per dormire (prescritti dal medico 
o comunque ottenuti)? 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
8. Nell’ultimo mese quante volte avete avuto difficoltà a restare svegli durante la guida, il 
pasto, un’attività sociale? 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
9. Nel mese passato, in che misura ha rappresentato per voi un problema avere abbastanza 
antusiasmo per fare ciò che dovevate fare? 
Nessun problema un piccolo problema un certo problema un problema grosso 
10. Avete un partner di letto o condividete la camera da letto con qualcuno? 
No il partner in un’altra camera stessa camera diverso letto stesso letto 
11. Se avete un partner o un compagno di camera domandategli quante volte nell’ultimo 
mese avete presentato: 
• Un forte russamento 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Lunghe pause respiratorie durante il sonno 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Movimenti o scosse delle gambe durante il sonno 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
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• Episodi di confusione o disorientamento durante il sonno 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
• Altri motivi di agitazione durante il sonno: 
Li descriva: 
mai meno di 1 volta/sett 1-2 volte/sett 3 o + volte/sett 
 
CALCOLO DEL PUNTEGGIO: 
 
Componente 1. Qualità soggettiva del sonno 
• Domanda 6: molto buona = 0; abbastanza buona = 1; abbastanza cattiva = 2; molto 
cattiva = 3. 
Punteggio: ___ 
Componente 2. Latenza del sonno 
• Domanda 2: <15 min: 0; 16-30 min: 1; 31-60 min: 2; >60min: 3 
punteggio___ 
• Domanda 5a: mai = 0; meno di 1 volta/sett = 1; 1-2 volte/sett = 2; 3 o + volte/sett = 3 
Punteggio___ 
• Somma domanda 2 + domanda5a: 0 = 0; 1-2 = 1; 3-4 = 2; 5-6 = 3 
Punteggio:___ 
Componente 3: durata del sonno 
• Domanda 4: >7 ore = 0; 6-7 ore = 1; 5-6 ore = 2; <5 ore = 3 
Punteggio___ 
Componente 4: efficienza abituale del sonno 
• n° di ore dormite (domanda 4): ___ 
• n° di ore trascorse a letto (vd. Domande 1 e 3):___ 
• calcolare l’efficienza del sonno in percentuale: (n° ore dormite/n° ore trascorse a letto) x 
100 
• attribuire il punteggio come segue: >85% = 0; 75-84% = 1; 65-74%= 2; < 65% = 3 
Punteggio ___ 
Componente 5: disturbi del sonno 
• esaminare le domande dalla 5b alla 5l e attribuire il punteggio per ogni domanda come 
segue: 
mai = 0; < 1 volta/sett = ; 1-2 volte /sett = 2; 3 o + volte/sett = 3 
• addizionare i punteggi da 5b a 5l 
• attribuire il punteggio come segue: 0 = 0; 1-9 = 1; 10-18 = 2; 19-27 = 3. 
Punteggio___ 
Componente 6: utilizzo di un farmaco per dormire 
• esaminare la domanda 7: mai = 0; <1 volta/sett = 1; 1-2 volte/sett = 2; 3 o + volte/sett = 
3. 
Punteggio___ 
Componente 7: cattivo stato di forma durante la giornata 
• esaminare la domanda 8: mai = 0; <1 volta/sett = 1; 1-2 volte/sett = 2; 3 o + volte/sett = 
3. ____ 
• esaminare la domanda 9: nessun problema = 0; piccolo problema = 1; un certo problema 
= 2; 
problema grosso = 3. ___ 
• addizionare i punteggi delle domande 8 e 9: ___ 
• attribuite il punteggio come segue (somma di 8 e 9): 0 = 0; 1-2 = 1; 3-4 = 2; 5-6 = 3 
Punteggio ____ 
 
Punteggio globale (somma delle 7 componenti): ____ 
 
Più il punteggio è vicino a 21 tanto più la qualità del sonno è scarsa 
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APPENDIX 4. Questionario di screening per il Disturbo del Comportamento 
in sonno REM (RBD) 
 
1. mi capita talvolta di fare sogni vividi (a contenuto intenso, con forte carica emotiva)  
SI \ NO 
2. i miei sogni hanno spesso contenuto aggressivo SI \ NO 
3. il contenuto dei miei sogni spesso correla con il mio comportamento nel sonno SI \ NO 
4. so di muovere le braccia e\o le gambe nel sonno SI \ NO 
5. mi capita talvolta nella concitazione del sogno, di colpire il partner o di farmi male      
SI \ NO 
6. ho, oppure ho presento i seguenti fenomeni in sonno: 
- parlare, gridare, imprecare o ridere forte SI \ NO 
- fare rapidi movimenti delle gambe come calciare SI \ NO 
- fare movimenti complessi o gesti che sono inusuali durante il sonno 
come ondeggiare, salutare, catturare zanzare, cadere dal letto SI \ NO 
- ritrovare oggetti caduti intorno al letto come la lampada, libri, occhiali etc SI \ NO 
7. mi capita che i miei movimenti mi sveglino SI \ NO 
8. al risveglio spesso ricordo chiaramente il contenuto dei miei sogni SI \ NO 
9. il mio sonno è frequentemente disturbato SI \ NO 
10. ho o ho avuto una patologia neurologica tra queste: ictus, trauma, parkinsonismo, 

















APPENDIX 5. Questionario di Berlino (**) 
 
 




1. Siete solito russare? 
_A. Sì 
_B. No 
_C. Non so 
 
2. Se russa: il suo russare è: 
_A. Leggermente più forte della respirazione 
_B. Più forte di chi parla 
_C. Più forte del parlare 
_D. Molto alto – può essere ascoltata in stanze adiacenti 
 
3. Le capita di russare: 
_A. Quasi ogni giorno 
_B. 3-4 volte a settimana 
_C. 1-2 volte a settimana 
_D. 1-2 volte al mese 
_E. Mai o quasi mai 
 
4. Il suo russare ha mai interessato altre persone? 
_A. Sì 
_B. No 
_C. Non so 
 
5. Qualcuno ha notato che interrompe la respirazione durante il sonno? 
_A. Quasi ogni giorno 
_B. 3-4 volte a settimana 
_C. 1-2 volte a settimana 
_D. 1-2 volte al mese 




6. Quante volte si sente stanco o affaticato dopo il sonno notturno? 
_A. Quasi ogni giorno 
_B. 3-4 volte a settimana 
_C. 1-2 volte a settimana 
_D. 1-2 volte al mese 
_E. Mai o quasi mai 
 
7. Durante il giorno si sente stanco, affaticato o svogliato? 
_A. Quasi ogni giorno 
_B. 3-4 volte a settimana 
_C. 1-2 volte a settimana 
_D. 1-2 volte al mese 
_E. Mai o quasi mai 
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In caso affermativo: 
 
9. Con quale frequenza si verifica il problema? 
_A. Quasi ogni giorno 
_B. 3-4 volte a settimana 
_C. 1-2 volte a settimana 
_D. 1-2 volte al mese 




10. Ha la pressione alta? Calcolare il BMI (Body Mass Index*) 
_ Sì 
_ No 
_ Non so 
 
 
*Body Mass Index = peso/altezza2                       Es.   Kg. 80  =    80    = 24,69 (B.M.I.) 
                                          m 1.80       3.24 
 
** Nikolaus C. Netzer, MD; Riccardo A. Stoohs, MD; Cordula M. Netzer; Kathryn 
Clark; and Kingman P. Strohl, MD.: Using the Berlin Questionnaire To Identify Patients 
at Risk for the Sleep Apnea Syndrome. ANN INTERN MED. 5 October 
1999;131(7):485-491.  
** Gross JB, Bachenberg KL, Benumof JL, Caplan RA, Connis RT, Cote CJ, 
Nickinovich DG, Prachand V, Ward DS, Weaver EM, Ydens L, Yu S: Practice guidelines 
for the perioperative management of patients with obstructive sleep apnea: A report by 
the American Society of Anesthesiologists Task Force on Perioperative Management of 
Patients with Obstructive Sleep Apnea. ANESTHESIOLOGY 2006; 104:1081–93 
 
PUNTEGGI QUESTIONARIO DI BERLINO 
Tratto da: NC Netzer, Stoohs RA, CM Netzer, Clark K, Strohl KP). Utilizzo del 
questionario di Berlino per identificare i pazienti a rischio per la sindrome delle apnee 
notturne. Tabella 2 - Ann Intern Med. 5 ottobre 1999; 131 (7) :485-91.  
 
Il questionario si compone di 3 categorie relative al rischio di apnea del sonno. I pazienti 
possono essere classificati ad alto rischio o basso rischio, sulla base delle loro risposte ai 
singoli elementi e con la valutazione complessiva nelle categorie sintomo.  
 
Categorie e punteggio:  
Categoria 1: punti 1, 2, 3, 4, 5.  
Punto 1: se 'Sì', assegnare 1 punto  
Punto 2: se 'c' o 'd' è la risposta, assegnare 1 punto  
Punto 3: se 'a' o 'b' è la risposta, assegnare 1 punto  
Punto 4: se 'a' è la risposta, assegnare 1 punto  
Punto 5: se 'a' o 'b' è la risposta, assegnare 2 punti  
Categoria 1 è positivo se il punteggio totale è di 2 o più punti  
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Categoria 2: articoli 6, 7, 8 (il punto 9 va osservato separatamente).  
Punto 6: se 'a' o 'b' è la risposta, assegnare 1 punto  
Punto 7: se 'a' o 'b' è la risposta, assegnare 1 punto  
Punto 8: se 'a' è la risposta, assegnare 1 punto  
Categoria 2 è positivo se il punteggio totale è di 2 o più punti  
 
Categoria 3 è positivo se la risposta al punto 10 è Sì  
(se il Body Mass Index del paziente è maggiore di 30kg/m2. (il BMI deve essere 
calcolato; è definito come peso (kg) diviso altezza (m) al quadrato, vale a dire, kg/m2).  
Ad alto rischio OSAS: 2 o più categorie positive 


































APPENDIX 6. Scala di valutazione della severità della RLS 
1. come giudica il Suo disagio\dolore alle gambe o agli arti? 





2. come valuta la necessità di muovere gli arti? 





3. che sollievo rileva rispetto al disagio prodotto dalla RLS con il movimento? 
(4) nessun sollievo 
(3) lieve sollievo 
(2) Moderato 
(l) totale 
(0) nessun disturbo RLS 
4. quale è il grado di compromissione del Suo sonno a seguito del disagio RLS? 





5. quale è il grado di stanchezza o la sonnolenza conseguente? 





6. nel complesso come giudica la gravità dei suoi disturbi alle gambe? 





7. che frequenza hanno i disturbi alle gambe? 
(4) Molto grave (6-7 giorni su sette) 
(3) Grave (4-5 giorni su 7) 
(2) Moderato (2-3 giorni su 7) 
(l) Lieve (1 giorno su 7) 
(0) nessuno 
8. come giudica la severità del disturbo nell’arco della giornata? 
(4) Molto grave (8 ore in media) 
(3) Grave (da 3 a 8 ore) 
(2) Moderato (1-3 ore) 
(l) Lieve ( meno di 1 ora) 
(0) nessuno 
9. come giudica l’impatto del disturbo alle gambe nella vita quotidiana e di 
relazione? 






10. in che modo il disturbo incide sul suo umore determinando ansia, depressione, 
irritabilità etc.? 
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